Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion. Dreamstime Text size Viatris , the company formed in 2020 through a merger of...
Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion. Dreamstime Text size Viatris , the company formed in 2020 through a merger of...